Remaining TC-5214 Phase III efficacy studies do not meet endpoint, regulatory filing will not be pursued
20 March 2012 | By AstraZeneca
Top-line results from the remaining Phase III studies - announced...
List view / Grid view
20 March 2012 | By AstraZeneca
Top-line results from the remaining Phase III studies - announced...
8 November 2011 | By AstraZeneca
Top-line results announced...
7 February 2011 | By AstraZeneca
This study is in addition to the companies’ Phase III RENAISSANCE programme for TC-5214...